Information Provided By:
Fly News Breaks for June 22, 2015
STEM
Jun 22, 2015 | 07:05 EDT
Cantor expects StemCells to report upbeat data for its Phase III clinical trial in dry age-related macular degeneration / Geographic Atrophy. It keeps a $2 price target and Buy rating on the shares.
News For STEM From the Last 2 Days
There are no results for your query STEM